Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Journal Title: OncoReview - Year 2011, Vol 1, Issue 2
Abstract
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled,double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. Thehypothesis was that octreotide LAR prolongs time to tumor progression and survival.Patients and Methods: Treatment-naive patients were randomly assigned to either placebo or octreotide LAR 30 mg intramuscularly in monthly intervals until tumor progression or death. The primary efficacy end point was time to tumor progression. Secondary end points were survival time and tumor response. This report is based on 67 tumor progressions and 16 observed deaths in 85 patients at the time of the planned interim analysis.Results: Median time to tumor progression in the octreotide LAR and placebo groups was 14.3 and 6 months, respectively (hazard ratio [HR]=0.34; 95% CI, 0.20 to 0.59; P=0,000072). After 6 months of treatment, stable disease was observed in 66.7% of patients in the octreotide LAR group and 37.2% of patients in the placebo group. Functionally active and inactive tumors responded similarly. The most favorable effect was observed in patients with low hepatic tumor load and resected primary tumor. Seven and nine deaths were observed in the octreotide LAR and placebo groups, respectively. The HR for overall survival was 0.81 (95% CI, 0.30 to 2.18).Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs. Because of the low number of observed deaths, survival analysis was not confirmatory.
Authors and Affiliations
Anja Rinke, Hans-Helge Muller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Blaker, Jan Harder, Christian Arnold, Thomas Gress, Rudolf Arnold
Keywords
Related Articles
- EP ID EP53101
- DOI -
- Views 223
- Downloads 0
Planning hormonal therapy in prostate cancer patients – expert view
In last decades prostate cancer became one of the most common cancers in the World, and one of the most common cancer death diagnosis. As a hormone-dependent entity for almost 70 years prostate cancer is treated with hor...
Percutaneous vena cava superior angioplasty and stenting as an effective method of treatment in vena cava superior syndrome in the course of lung cancer
Vena cava superior syndrome (VCSS) is a sudden life-threatening condition encountered in patients with neoplasms. The prognosis depends on histopathological diagnosis, severity of clinical symptoms and administered treat...
Percutaneous retrieval of a fractured portacath fragment in two patients undergoing long-term chemotherapy
The paper discusses two clinical cases of cancer patients undergoing chemotherapy, in whom fractured and displaced tips of portacath catheters were revealed based on plain chest imaging. In the first case, the portacath...
Zespół rozpadu guza
Zespół rozpadu guza jest stanem zagrożenia życia występującym u pacjentów z rozległymi nowotworami, u których pod wpływem chemioterapii bądź samoistnie dochodzi do masywnego rozpadu komórek nowotworowych z uwolnieniem ic...
Squamous cell oesophageal cancer in retinoblastoma survivor: does germinal RB1 mutation influence chemo- and radiosensitivity?
The case of complete response of squamous cell oesophageal cancer to radiochemotherapy in patient previously operated due to hereditary retinoblastoma is presented. Second cancers in retinoblastoma survivors are the main...